OpenFilings

BiomX Inc.

Form10-K

Report Period2023-12-31

Date Filed2024-04-04

Time Filed06:30:39

Document Analysis

Natural Language Processing

Recognized Type Unidentified

Defined Term Format

Exhibits

ANNUAL REPORT
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EX
FORM OF INDEMNIFICATION AGREEMENT
EXCLUSIVE LICENSE BETWEEN ADAPTIVE PHAGE THERAPEUTICS, INC. AND UNITED STATES OF
FIRST AMENDMENT, DATED JANUARY 10, 2019, TO EXCLUSIVE LICENSE BETWEEN ADAPTIVE P
NON-EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN ADAPTIVE PHAGE THERAPEUTICS, INC.
LICENSE MODIFICATION 1, DATED AUGUST 31, 2022, TO NON-EXCLUSIVE LICENSE AGREEMEN
LEASE AGREEMENT, DATED AS OF AUGUST 9, 2019, BY AND BETWEEN ARE-708 QUINCE ORCHA
AMENDMENT NO. 1, DATED AS OF OCTOBER 28, 2020, TO LEASE AGREEMENT BY AND BETWEEN
AMENDMENT NO. 2, DATED AS OF JULY 8, 2021, TO LEASE AGREEMENT BY AND BETWEEN ARE
AMENDMENT NO. 3, DATED AS OF JULY 15, 2021, TO LEASE AGREEMENT BY AND BETWEEN AR
AMENDMENT NO. 4, DATED AS OF SEPTEMBER 27, 2022, TO LEASE AGREEMENT BY AND BETWE
AMENDMENT NO. 5, DATED AS OF FEBRUARY 2, 2023, TO LEASE AGREEMENT BY AND BETWEEN
AMENDMENT NO. 6, DATED AS OF MARCH 5, 2024, TO LEASE AGREEMENT BY AND BETWEEN AR
SUBSIDIARIES OF COMPANY
CONSENT OF KESSELMAN & KESSELMAN, CERTIFIED PUBLIC ACCOUNTANTS (ISR.), A MEMBER
CERTIFICATION
CERTIFICATION
CERTIFICATION
CLAWBACK POLICY
RESOLUTIONS OF BOARD OF DIRECTORS RATIFYING STOCK ISSUANCE
Filing on SEC Edgar